Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
Open Access
Abstract
SLC2A1 plays a pivotal role in cancer glycometabolism. SLC2A1 has been proposed as a putative driver gene in various cancers. However, a pan-cancer analysis of SLC2A1 has not yet been performed. In this study, we explored the expression and prognosis of SLC2A1 in pan-cancer across multiple databases. We conducted genetic alteration, epigenetic, and functional enrichment analyses of SLC2A. We calculated the correlation between SLC2A1 and tumor microenvironment using the TCGA pan-cancer dataset. We observed high expression levels of SLC2A1 with poor prognosis in most cancers. The overall genetic alteration frequency of SLC2A1 was 1.8% in pan-cancer, and the SLC2A1 promoter was hypomethylation in several cancers. Most m6A-methylation-related genes positively correlated with the expression of SLC2A1 in 33 TCGA cancers. Moreover, SLC2A1 was mainly related to the functions including epithelial–mesenchymal transition, glycolysis, hypoxia, cell-cycle regulation, and DNA repair. Finally, SLC2A1 positively associated with neutrophils and cancer-associated fibroblasts in the tumor microenvironment of most cancers and significantly correlated with TMB and MSI in various cancers. Notably, SLC2A1 was remarkably positively correlated with PD-L1 and CTLA4 in most cancers. SLC2A1 might serve as an attractive pan-cancer biomarker for providing new insights into cancer therapeutics.Keywords
Funding Information
- scientific research of the Sixth Affiliated Hospital, Sun Yat-sen University (P20200217202404781)
This publication has 60 references indexed in Scilit:
- Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancerLung Cancer, 2015
- Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHAClinical Cancer Research, 2015
- Metabolic pathways promoting cancer cell survival and growthNature Cell Biology, 2015
- Metabolic Phenotypes in Pancreatic CancerPLOS ONE, 2015
- Inferring tumour purity and stromal and immune cell admixture from expression dataNature Communications, 2013
- Oxygen metabolism in oral cancer: HIF and GLUTs (Review)Oncology Letters, 2013
- Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistryJournal of Translational Medicine, 2013
- T cell exhaustionNature Immunology, 2011
- Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tractPathology - Research and Practice, 2010
- GLUT1 and GLUT8 in endometrium and endometrial adenocarcinomaLaboratory Investigation, 2006